people with advanced kidney cancer, blood pressure appears to indicate how their medication works well, with a high blood pressure linked to longer survival, new research shows.
The conclusion comes from a study of 544 people being treated with the drug sunitinib (Sutent) for advanced kidney cancer. The researchers found that those with systolic blood pressure maximum reached 140 mmHg or more survived nearly four times longer than those who had a lower maximum arterial systolic - 30, 5 months against 7.8 months.
Systolic is high number and diastolic blood pressure reading less number.
Those who had a maximum diastolic blood pressure 90 mmHg or more survived two times longer that those with a diastolic blood pressure of maximum bottom - 32, 2 months vs 14.9 months.
Also, the researchers found that progression-free survival, which refers to the amount of time when a tumour to be reduced or not, growing was 2.5 to 5 times longer in people with high blood pressure - 12, 5 months for persons suffering from hypertension systolic vs. 2.5 months for those who did ontet 13.4 months for persons with arterial hypertension diastolic vs 5.3 months for those without.
"These observations confirm the hypothesis that high blood pressure can act as a biomarker of antitumor efficacy of the drug," study leader Dr. Brian Rini, personal physician to Taussig Cancer Institute the Cleveland Clinic, said in a press release of clinic. "What this means is that doctors may be able to monitor the blood pressure of the patient to measure the degree of effectiveness sunitinib is to treat advanced kidney cancer.".
The study was published online on April 28 in the journal of the National Cancer Institute.
No comments:
Post a Comment